The solid-state laser advantage

Article

Clinical outcomes of laser epithelial keratomileusis using a 213 nm wavelength solid-state laser

The 213 nm wavelength generated by solid state platforms (e.g., Pulzar Z1, CustomVis, Perth, Australia) demonstrates superior transmissibility through water compared to 193 nm, so is less sensitive to levels of corneal hydration, and may reduce the variability in refractive outcomes linked with corneal hydration; corneas that become dehydrated during excimer laser treatment are often overcorrected, while superhydration is linked with undercorrection.3 Furthermore, the absence of dangerous gas eliminates sudden noise, and patient anxiety, as laser operation commences, while maintenance costs are also substantially reduced.

Clinical outcomes

Earlier this year, we reported outcomes from a cohort of patients undergoing laser epithelial keratomileusis (LASEK) performed by the same surgeon using the CustomVis solid-state refractive laser.8 The CustomVis system generates a 213 nm wavelength by transmission of a 1064 nm Nd:YAG laser beam through three non-linear crystals. The 0.6 mm diameter quasi-Gaussian-shaped flying spot has a 300 Hz pulse repetition rate, and the system employs three methods of eye tracking technology: a limbus-based eye tracker with a closed-loop response of 1-kHz, a video eye tracker to facilitate a higher level of accuracy and a video gaze tracker, confirming patient fixation.

The cohort included 245 eyes of 134 patients with a mean age of 41.0 ± 12.2 years. Patients had a broad range of preoperative refractive errors, with sphere values ranging from –9.50 to +6.50 D (mean –1.59 ± 3.22 D) and astigmatism between 0 and –5.50 D (mean –0.98 ± 1.17 D). Postoperative follow-up visits were scheduled at 2 and 6 months.

LASEK surgery performed on this substantial cohort was shown to be effective, safe and stable over the follow-up period. Over 95% of eyes maintained the same best corrected distance visual acuity (CDVA) postoperatively, or gained a line, and the mean postoperative spherical equivalent refractive error (SE) was stable between the 2 month (–0.01 ± 0.57 D) and 6 month (–0.01 ± 0.55 D) visits. Treatment was accurate for both myopes and hyperopes, with mean SEs at 6 months of +0.02 ± 0.27 D and 0.21 ± 0.66 D, respectively.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.